<p>Magnetar Financial LLC 在第一季度收购了辉瑞公司（NYSE:PFE - 免费报告）的新股份，根据该公司最近向证券交易委员会提交的 13F 文件。该基金收购了 71,927 股生物制药公司的股票，价值约为 1,823,000 美元。</p>
<ul>
<li>3 只长期分红股票，价格低于 50 美元</li>
</ul>
<p>其他一些机构投资者最近也对其在该公司的持股进行了调整。先锋集团（Vanguard Group Inc.）在第一季度将其在辉瑞的持股增加了 0.9%。先锋集团目前拥有辉瑞 523,165,127 股股票，价值为 13,257,004,000 美元，在上个季度又购买了 4,629,976 股。北方信托公司（Northern Trust Corp）在第一季度将其在辉瑞的持股增加了 6.8%。北方信托公司目前拥有辉瑞 62,325,957 股股票，价值为 1,579,340,000 美元，在上个季度又收购了 3,943,397 股。瑞银资产管理（UBS AM）作为瑞银资产管理美洲公司的一个独立业务单位，在第四季度将其在辉瑞的持股增加了 3.5%。瑞银资产管理目前拥有辉瑞 39,402,619 股股票，价值为 1,045,351,000 美元，在上个季度又收购了 1,333,740 股。景顺（Invesco Ltd.）在第一季度将其在辉瑞的持股增加了 2.8%。景顺目前拥有辉瑞 30,296,337 股股票，价值为 767,709,000 美元，在上个季度又收购了 838,198 股。最后，德意志银行（Deutsche Bank AG）在第一季度将其在辉瑞的持股增加了 7.0%。德意志银行目前拥有辉瑞 28,239,197 股股票，价值为 715,581,000 美元，在上个季度又收购了 1,846,436 股。机构投资者和对冲基金持有该公司 68.36% 的股份。</p>
<h2>辉瑞股票上涨 0.6%</h2>
<p>辉瑞（NYSE:PFE）股票周五开盘价为 24.74 美元。该公司的 50 日简单移动平均为 24.79 美元，200 日简单移动平均为 24.38 美元。辉瑞公司的 12 个月最低价为 20.92 美元，最高价为 30.43 美元。该公司的市值为 1,406.5 亿美元，市盈率为 13.16，市盈增长比率为 0.88，贝塔值为 0.52。该公司的流动比率为 1.16，速动比率为 0.85，债务股本比率为 0.65。</p>
<ul>
<li>医疗保健股票估值触底，3 只股票有反弹潜力</li>
</ul>
<p>辉瑞（NYSE:PFE - 获取免费报告）最近于 8 月 5 日发布了季度财报。这家生物制药公司报告本季度每股收益（EPS）为 0.78 美元，超出市场共识预期的 0.58 美元，超出幅度为 0.20 美元。辉瑞的净利润率为 16.84%，股本回报率为 21.42%。该公司本季度的收入为 146.5 亿美元，而市场共识预期为 134.3 亿美元。去年同期，该公司每股收益为 0.60 美元。辉瑞本季度的收入同比增长 10.3%。辉瑞已将 2025 财年的指引设定为每股收益 2.900-3.100 美元。分析师平均预测辉瑞公司本财年的每股收益为 2.95 美元。</p>
<h2>辉瑞分红公告</h2>
<p>该公司最近还披露了季度分红，将于 9 月 2 日（星期二）支付。7 月 25 日（星期五）登记在册的股东将获得 0.43 美元的分红。这代表着每年 1.72 美元的分红和 7.0% 的收益率。该分红的除息日为 7 月 25 日（星期五）。辉瑞的派息比率目前为 91.49%。</p>
<h2>分析师设定新目标价</h2>
<ul>
<li>5 只被低估的分红股票，具有强劲的派息潜力</li>
</ul>
<p>辉瑞的股票已成为多份分析师报告的主题。杰富瑞金融集团（Jefferies Financial Group）在 5 月 21 日的报告中将辉瑞的目标价从 32.00 美元上调至 33.00 美元，并给予该股票 “买入” 评级。汇丰银行（HSBC）在 5 月 19 日的报告中将辉瑞的目标价从 27.00 美元下调至 26.00 美元，并为该公司设定了 “买入” 评级。花旗集团（Citigroup）在 8 月 6 日的报告中将辉瑞的目标价从 25.00 美元上调至 26.00 美元，并给予该股票 “中性” 评级。摩根士丹利（Morgan Stanley）在 8 月 6 日的报告中将辉瑞的目标价从 32.00 美元上调至 33.00 美元，并给予该股票 “同等权重” 评级。最后，美国银行（Bank of America）在 8 月 6 日的研究报告中将辉瑞的目标价从 27.00 美元上调至 28.00 美元，并给予该股票 “中性” 评级。两位研究分析师对该股票给予 “强烈买入” 评级，四位给予 “买入” 评级，十一位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “持有”，共识目标价为 28.12 美元。</p>
<p><strong>阅读我们最新的辉瑞股票报告</strong></p>
<h2>辉瑞公司简介</h2>
<p>（免费报告）</p>
<p>辉瑞公司在美国、欧洲及国际市场上发现、开发、制造、营销、分销和销售生物制药产品。该公司在多个治疗领域提供药物和疫苗，包括心血管代谢、偏头痛和女性健康，旗下品牌包括 Eliquis、Nurtec ODT/Vydura、Zavzpret 和 Premarin 系列；在满足医疗需求的传染病领域，旗下品牌包括 Prevnar 系列、Abrysvo、Nimenrix、FSME/IMMUN-TicoVac 和 Trumenba；以及 COVID-19 的预防和治疗，以及潜在的未来 mRNA 和抗病毒产品，旗下品牌包括 Comirnaty 和 Paxlovid。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，胜过辉瑞</li>
<li>便士股票适合你的投资组合吗？</li>
<li>DICKS 运动用品公司股票在财报后下跌——值得购买吗？</li>
<li>如何计算退休收入：MarketBeat 的计算器</li>
<li>AI 引擎：康明斯的意外增长动力</li>
<li>投资中的降级意味着什么？</li>
<li>小型工业公司看到激增的增长：原因在这里</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ"/></p>
<p><em>这条即时新闻提醒是由叙事科学技术和来自 MarketBeat 的金融数据生成的，旨在为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审查。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在辉瑞吗？</h2>
<p>在考虑辉瑞之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而辉瑞并不在名单上。</p>
<p>虽然辉瑞目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

辉瑞

<p>Magnetar Financial LLC 已经收购了辉瑞公司（NYSE:PFE）的一项新股份，购买了 71,927 股，价值约为 182 万美元。其他机构投资者，包括先锋集团和北方信托，也增加了他们在辉瑞的持股。该公司的股票开盘价为 24.74 美元，市值为 1406.5 亿美元。辉瑞最近报告的季度每股收益为 0.78 美元，超出预期，并宣布季度股息为 0.43 美元。分析师已调整了辉瑞的目标价格，评级范围从 “买入” 到 “中性”</p>

<p>Magnetar Financial LLC acquired a new stake in Pfizer Inc. (NYSE:PFE - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities &amp; Exchange Commission. The fund acquired 71,927 shares of the biopharmaceutical company's stock, valued at approximately $1,823,000.</p>
<div class="lb-trans"><p>Magnetar Financial LLC 在第一季度收购了辉瑞公司（NYSE:PFE - 免费报告）的新股份，根据该公司最近向证券交易委员会提交的 13F 文件。该基金收购了 71,927 股生物制药公司的股票，价值约为 1,823,000 美元。</p>
</div><ul>
<li>3 Long-Term Dividend Buys You Can Get for Under $50</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只长期分红股票，价格低于 50 美元</li>
</ul>
</div><p>A number of other institutional investors have also recently made changes to their positions in the business. Vanguard Group Inc. grew its holdings in shares of Pfizer by 0.9% in the first quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company's stock valued at $13,257,004,000 after purchasing an additional 4,629,976 shares in the last quarter. Northern Trust Corp grew its holdings in Pfizer by 6.8% during the 1st quarter. Northern Trust Corp now owns 62,325,957 shares of the biopharmaceutical company's stock worth $1,579,340,000 after acquiring an additional 3,943,397 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Pfizer by 3.5% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 39,402,619 shares of the biopharmaceutical company's stock worth $1,045,351,000 after acquiring an additional 1,333,740 shares in the last quarter. Invesco Ltd. grew its holdings in Pfizer by 2.8% during the 1st quarter. Invesco Ltd. now owns 30,296,337 shares of the biopharmaceutical company's stock worth $767,709,000 after acquiring an additional 838,198 shares in the last quarter. Finally, Deutsche Bank AG grew its holdings in Pfizer by 7.0% during the 1st quarter. Deutsche Bank AG now owns 28,239,197 shares of the biopharmaceutical company's stock worth $715,581,000 after acquiring an additional 1,846,436 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.</p>
<div class="lb-trans"><p>其他一些机构投资者最近也对其在该公司的持股进行了调整。先锋集团（Vanguard Group Inc.）在第一季度将其在辉瑞的持股增加了 0.9%。先锋集团目前拥有辉瑞 523,165,127 股股票，价值为 13,257,004,000 美元，在上个季度又购买了 4,629,976 股。北方信托公司（Northern Trust Corp）在第一季度将其在辉瑞的持股增加了 6.8%。北方信托公司目前拥有辉瑞 62,325,957 股股票，价值为 1,579,340,000 美元，在上个季度又收购了 3,943,397 股。瑞银资产管理（UBS AM）作为瑞银资产管理美洲公司的一个独立业务单位，在第四季度将其在辉瑞的持股增加了 3.5%。瑞银资产管理目前拥有辉瑞 39,402,619 股股票，价值为 1,045,351,000 美元，在上个季度又收购了 1,333,740 股。景顺（Invesco Ltd.）在第一季度将其在辉瑞的持股增加了 2.8%。景顺目前拥有辉瑞 30,296,337 股股票，价值为 767,709,000 美元，在上个季度又收购了 838,198 股。最后，德意志银行（Deutsche Bank AG）在第一季度将其在辉瑞的持股增加了 7.0%。德意志银行目前拥有辉瑞 28,239,197 股股票，价值为 715,581,000 美元，在上个季度又收购了 1,846,436 股。机构投资者和对冲基金持有该公司 68.36% 的股份。</p>
</div><h2>Pfizer Stock Up 0.6%</h2>
<div class="lb-trans"><h2>辉瑞股票上涨 0.6%</h2>
</div><p>Shares of NYSE:PFE opened at $24.74 on Friday. The firm has a 50 day simple moving average of $24.79 and a 200-day simple moving average of $24.38. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $30.43. The company has a market capitalization of $140.65 billion, a PE ratio of 13.16, a P/E/G ratio of 0.88 and a beta of 0.52. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.</p>
<div class="lb-trans"><p>辉瑞（NYSE:PFE）股票周五开盘价为 24.74 美元。该公司的 50 日简单移动平均为 24.79 美元，200 日简单移动平均为 24.38 美元。辉瑞公司的 12 个月最低价为 20.92 美元，最高价为 30.43 美元。该公司的市值为 1,406.5 亿美元，市盈率为 13.16，市盈增长比率为 0.88，贝塔值为 0.52。该公司的流动比率为 1.16，速动比率为 0.85，债务股本比率为 0.65。</p>
</div><ul>
<li>Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound</li>
</ul>
<div class="lb-trans"><ul>
<li>医疗保健股票估值触底，3 只股票有反弹潜力</li>
</ul>
</div><p>Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter in the prior year, the firm earned $0.60 EPS. Pfizer's revenue for the quarter was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>辉瑞（NYSE:PFE - 获取免费报告）最近于 8 月 5 日发布了季度财报。这家生物制药公司报告本季度每股收益（EPS）为 0.78 美元，超出市场共识预期的 0.58 美元，超出幅度为 0.20 美元。辉瑞的净利润率为 16.84%，股本回报率为 21.42%。该公司本季度的收入为 146.5 亿美元，而市场共识预期为 134.3 亿美元。去年同期，该公司每股收益为 0.60 美元。辉瑞本季度的收入同比增长 10.3%。辉瑞已将 2025 财年的指引设定为每股收益 2.900-3.100 美元。分析师平均预测辉瑞公司本财年的每股收益为 2.95 美元。</p>
</div><h2>Pfizer Dividend Announcement</h2>
<div class="lb-trans"><h2>辉瑞分红公告</h2>
</div><p>The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.0%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's payout ratio is currently 91.49%.</p>
<div class="lb-trans"><p>该公司最近还披露了季度分红，将于 9 月 2 日（星期二）支付。7 月 25 日（星期五）登记在册的股东将获得 0.43 美元的分红。这代表着每年 1.72 美元的分红和 7.0% 的收益率。该分红的除息日为 7 月 25 日（星期五）。辉瑞的派息比率目前为 91.49%。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><ul>
<li>Top 5 Undervalued Dividend Stocks With Strong Payout Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>5 只被低估的分红股票，具有强劲的派息潜力</li>
</ul>
</div><p>PFE has been the subject of several analyst reports. Jefferies Financial Group boosted their price target on shares of Pfizer from $32.00 to $33.00 and gave the stock a &#34;buy&#34; rating in a report on Wednesday, May 21st. HSBC lowered their price target on shares of Pfizer from $27.00 to $26.00 and set a &#34;buy&#34; rating for the company in a report on Monday, May 19th. Citigroup boosted their price target on shares of Pfizer from $25.00 to $26.00 and gave the stock a &#34;neutral&#34; rating in a report on Wednesday, August 6th. Morgan Stanley boosted their price target on shares of Pfizer from $32.00 to $33.00 and gave the stock an &#34;equal weight&#34; rating in a report on Wednesday, August 6th. Finally, Bank of America boosted their price objective on shares of Pfizer from $27.00 to $28.00 and gave the stock a &#34;neutral&#34; rating in a research report on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of &#34;Hold&#34; and a consensus price target of $28.12.</p>
<div class="lb-trans"><p>辉瑞的股票已成为多份分析师报告的主题。杰富瑞金融集团（Jefferies Financial Group）在 5 月 21 日的报告中将辉瑞的目标价从 32.00 美元上调至 33.00 美元，并给予该股票 “买入” 评级。汇丰银行（HSBC）在 5 月 19 日的报告中将辉瑞的目标价从 27.00 美元下调至 26.00 美元，并为该公司设定了 “买入” 评级。花旗集团（Citigroup）在 8 月 6 日的报告中将辉瑞的目标价从 25.00 美元上调至 26.00 美元，并给予该股票 “中性” 评级。摩根士丹利（Morgan Stanley）在 8 月 6 日的报告中将辉瑞的目标价从 32.00 美元上调至 33.00 美元，并给予该股票 “同等权重” 评级。最后，美国银行（Bank of America）在 8 月 6 日的研究报告中将辉瑞的目标价从 27.00 美元上调至 28.00 美元，并给予该股票 “中性” 评级。两位研究分析师对该股票给予 “强烈买入” 评级，四位给予 “买入” 评级，十一位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “持有”，共识目标价为 28.12 美元。</p>
</div><p><strong>Read Our Latest Stock Report on PFE</strong></p>
<div class="lb-trans"><p><strong>阅读我们最新的辉瑞股票报告</strong></p>
</div><h2>Pfizer Profile</h2>
<div class="lb-trans"><h2>辉瑞公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.</p>
<div class="lb-trans"><p>辉瑞公司在美国、欧洲及国际市场上发现、开发、制造、营销、分销和销售生物制药产品。该公司在多个治疗领域提供药物和疫苗，包括心血管代谢、偏头痛和女性健康，旗下品牌包括 Eliquis、Nurtec ODT/Vydura、Zavzpret 和 Premarin 系列；在满足医疗需求的传染病领域，旗下品牌包括 Prevnar 系列、Abrysvo、Nimenrix、FSME/IMMUN-TicoVac 和 Trumenba；以及 COVID-19 的预防和治疗，以及潜在的未来 mRNA 和抗病毒产品，旗下品牌包括 Comirnaty 和 Paxlovid。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Pfizer</li>
<li>Are Penny Stocks a Good Fit for Your Portfolio?</li>
<li>DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy?</li>
<li>How to Calculate Retirement Income: MarketBeat’s Calculator</li>
<li>Engines to AI: Cummins’ Surprising Growth Driver</li>
<li>What Does Downgrade Mean in Investing?</li>
<li>Smaller Industrials Names Seeing Surging Growth: Here's Why</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过辉瑞</li>
<li>便士股票适合你的投资组合吗？</li>
<li>DICKS 运动用品公司股票在财报后下跌——值得购买吗？</li>
<li>如何计算退休收入：MarketBeat 的计算器</li>
<li>AI 引擎：康明斯的意外增长动力</li>
<li>投资中的降级意味着什么？</li>
<li>小型工业公司看到激增的增长：原因在这里</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=PFE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这条即时新闻提醒是由叙事科学技术和来自 MarketBeat 的金融数据生成的，旨在为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审查。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Pfizer Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在辉瑞吗？</h2>
</div><p>Before you consider Pfizer, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑辉瑞之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而辉瑞并不在名单上。</p>
</div><p>While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然辉瑞目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Magnetar Financial LLC Acquires New Position in Pfizer Inc. $PFE

- Magnetar Financial LLC 在第一季度收购了 Pfizer Inc. 的 71,927 股股票，价值约 182.3 万美元。  
- 多家机构投资者也增加了对 Pfizer 的持股，Vanguard 增持 0.9%，Northern Trust 增持 6.8%。  
- Pfizer 最近公布的季度收益为每股 0.78 美元，超出预期，营收同比增长 10.3%。  

Magnetar Financial LLC 在辉瑞公司（Pfizer Inc.）$PFE 中获得新的持仓